Ascrinvacumab

Ascrinvacumab (pronounced as-krin-va-koo-mab) is a monoclonal antibody designed for the treatment of various cancer types. It is a type of biological therapy that targets specific proteins on cancer cells to inhibit their growth and spread.

Etymology

The name "Ascrinvacumab" follows the World Health Organization's guidelines for the nomenclature of monoclonal antibodies. The suffix "-mab" indicates that it is a monoclonal antibody, while the infix "-vac-" suggests its cancer-related use.

Usage

Ascrinvacumab is used in the treatment of various types of cancer, including breast cancer, lung cancer, and colorectal cancer. It works by binding to specific proteins on the surface of cancer cells, inhibiting their ability to grow and spread.

Related Terms

Monoclonal antibody: A type of protein made in the lab that can bind to substances in the body, including cancer cells.
Biological therapy: Treatment to stimulate or restore the ability of the immune system to fight cancer, infections, and other diseases.
Cancer: A group of diseases characterized by the uncontrolled growth and spread of abnormal cells.
Breast cancer: A cancer that forms in the cells of the breasts.
Lung cancer: A type of cancer that begins in the lungs.
Colorectal cancer: A cancer that starts in the colon or the rectum.